Patents Assigned to SERVIER PHARMACEUTICALS LLC
-
Patent number: 11865079Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a purified compound described herein.Type: GrantFiled: February 10, 2022Date of Patent: January 9, 2024Assignee: Servier Pharmaceuticals LLCInventor: Chandra Agarwal Prakash
-
Patent number: 11851417Abstract: Provided are solid forms of a compound useful for treating cancer, pharmaceutical compositions thereof, and methods of treating cancer comprising administering the solid forms described herein to a patient in need thereof.Type: GrantFiled: April 19, 2022Date of Patent: December 26, 2023Assignee: Servier Pharmaceuticals LLCInventors: Benjamin S. Lane, Chong-Hui Gu
-
Patent number: 11844758Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.Type: GrantFiled: January 26, 2021Date of Patent: December 19, 2023Assignee: Servier Pharmaceuticals LLCInventors: Zenon Konteatis, Janeta Popovici-Muller, Jeremy Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
-
Publication number: 20230285365Abstract: Provided herein are method of treating lymphomas using an anti-cancer agent and an anti-cancer therapy, wherein the first anti-cancer agent is represented by Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 26, 2021Publication date: September 14, 2023Applicant: Servier Pharmaceuticals LLCInventors: John Coco, Brandon Nicolay
-
Patent number: 11717512Abstract: The present invention provides methods for treating cancer in a subject with a trisubstituted benzotriazole derivative with the formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2 and R3 are as defined herein.Type: GrantFiled: February 19, 2019Date of Patent: August 8, 2023Assignee: Servier Pharmaceuticals LLCInventors: Danielle Ulanet, Sung Eun Choe
-
Patent number: 11667673Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.Type: GrantFiled: June 5, 2020Date of Patent: June 6, 2023Assignee: Servier Pharmaceuticals LLCInventors: Janeta Popovici-Muller, Rene M. Lemieux, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
-
Patent number: 11524960Abstract: The present disclosure provides for compounds according to Formula I or Formula II and their pharmaceutically acceptable salts, stereoisomers, and/or tautomers thereof. Also provided are pharmaceutical compositions and the compounds of formulae I and II for use in methods of treating cancers, via inhibition of MAT2A, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted and/or not fully functioning.Type: GrantFiled: March 28, 2019Date of Patent: December 13, 2022Assignee: SERVIER PHARMACEUTICALS LLCInventors: Zenon D. Konteatis, Mingzong Li, Peng Liu, Matthew Medeiros, Samuel K. Reznik, Zhihua Sui, Jeremy M. Travins, Janeta Popovici-Muller, Shubao Zhou, Guangning Ma
-
Patent number: 11504361Abstract: Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein.Type: GrantFiled: September 4, 2020Date of Patent: November 22, 2022Assignee: SERVIER PHARMACEUTICALS LLCInventor: Chong-Hui Gu
-
Patent number: 11505538Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.Type: GrantFiled: June 18, 2020Date of Patent: November 22, 2022Assignee: Servier Pharmaceuticals LLCInventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
-
Patent number: 11419859Abstract: Provided are methods and compositions for treating acute myelogenous leukemia (AML) in patients carrying an IDH1 mutation using an inhibitor of a mutant IDH1 enzyme, (S)—N—((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide in combination with cytarabine and doxorubicin or idarubicin as an induction therapy and either cytarabine or a combination of combination of mitoxantrone and etoposide as consolidation therapy.Type: GrantFiled: October 14, 2016Date of Patent: August 23, 2022Assignee: SERVIER PHARMACEUTICALS LLCInventor: Samuel V. Agresta
-
Patent number: 11389454Abstract: Provided herein is a tablet comprising 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 6, 2017Date of Patent: July 19, 2022Assignees: CELGENE CORPORATION, SERVIER PHARMACEUTICALS LLCInventors: Sreenivas S. Bhat, Scott Burnside, Darshan Parikh, Chong-Hui Gu, Syed Altaf
-
Publication number: 20220169654Abstract: The present application provides MAT2A inhibitor compounds that are useful as therapeutic agents. In some embodiments, the compounds are of Formula I, or pharmaceutically acceptable salts thereof: wherein R1, R2, and X1-X3 are defined herein.Type: ApplicationFiled: November 24, 2021Publication date: June 2, 2022Applicant: Servier Pharmaceuticals LLCInventors: Zenon D. KONTEATIS, Mingzong LI, Samuel K. REZNIK, Zhihua SUI
-
Patent number: 11345677Abstract: Provided are solid forms of a compound useful for treating cancer, pharmaceutical compositions thereof, and methods of treating cancer comprising administering the solid forms described herein to a patient in need thereof.Type: GrantFiled: November 2, 2018Date of Patent: May 31, 2022Assignee: Servier Pharmaceuticals LLCInventors: Benjamin S. Lane, Chong-Hui Gu
-
Patent number: 11325914Abstract: The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.Type: GrantFiled: August 24, 2020Date of Patent: May 10, 2022Assignee: SERVIER PHARMACEUTICALS LLCInventors: Zenon D. Konteatis, Zhihua Sui, Jeremy M. Travins, Zhixiong Ye
-
Patent number: RE49934Abstract: The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.Type: GrantFiled: March 8, 2022Date of Patent: April 23, 2024Assignee: Servier Pharmaceuticals LLCInventors: Zenon D. Konteatis, Zhihua Sui, Jeremy M. Travins, Zhixiong Ye
